Baseline characteristics of the patients with DON included in the meta-analysis
| Study . | Year . | Country . | Study design . | Patients (n) . | Sex (M/ F) . | Orbits (n) . | Mean age (y) . | Intervention . | OD (Orbits) . | Mean follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Wakelkamp et al (9) | 2005 | Netherlands | RCT | 15 | 2/13 | 15 | 52 | ivGC, OD | 3-walls | ivGC: 78 ± 15.5 OD: 64 ± 13 |
| Simon et al (13) | 2006 | Israel | RCS | 20 | 4/16 | 26 | 50.3 ± 15.7 | ivGC + OD | 2-walls: 6 | 17 ± 9 |
| Liao et al (14) | 2006 | Taiwan, China | RCS | 22 | 8/14 | 38 | 58.4 | ivGC + OD | 2-walls | 22.3 ± 12.8 |
| Lipski et al (15) | 2011 | Germany | RCS | 15 | 1/14 | 30 | 56.2 ± 10.88 | OD | 3-walls | 30 ± 13 |
| Wu et al (10) | 2011 | China | RCS | 29 | 10/19 | 45 | 44.8 ± 13.8 | OD | 2-walls | 17.4 ± 5.6 |
| Baril et al (16) | 2014 | Spain | RCS | 34 | 20/39 | 59 | 57.80 ± 11.89 | ivGC + OD | 2-walls | 132 |
| Korkmaz et al (17) | 2015 | Turkey | RCS | 42 | 25/17 | 68 | 53.5 | OD | 2-walls: 41 3-walls: 27 | 39.3 ± 15 |
| Lv et al (18) | 2015 | China | RCS | 43 | 12/31 | 72 | 45 | OD | fat decompression | 9 ± 3 |
| Kuebler et al (19) | 2020 | Germany | RA | 25 | 5/20 | 46 | ivGC: 62 ivGC + OD: 55 | ivGC, ivGC + OD | 3-walls | ivGC: 12 ± 12.55 ivGC + OD:10.1 ± 4.51 |
| Tagami et al (20) | 2020 | Japan | RCS | 44 | 15/29 | 70 | 53.4 ± 8.9 | OD | 2-walls | 40.9 ± 21.2 |
| Woods et al (21) | 2020 | Ireland | RA | 22 | 7/15 | 17 | 52 | ivGC + OD | 2-walls | 3 ± 0 |
| Xu et al (5) | 2020 | China | PCS | 23 | 15/8 | 46 | 58.3 ± 8.93 | ivGC, ivGC + OD | 2-walls | 3 ± 0 |
| Cheng et al (22) | 2021 | China | RCS | 37 | 9/28 | 52 | 48.27 ± 10.59 | OD | 2-walls:31 3-walls:21 | 22 ± 17 |
| Tu et al (23) | 2021 | China | RA | 42 | 24/18 | 74 | 57.30 ± 9.29 | OD | 2-walls | 6 ± 1.5 |
| Rezar-Dreindl et al (3) | 2022 | Austria | RA | 49 | 12/37 | 98 | 52 ± 14 | ivGC, OD, ivGC + OD | 2-walls:8 3-walls:30 | 49.2 ± 33.6 |
| Yun et al (2) | 2022 | Taiwan, China | RA | 11 | 9/2 | 16 | 60.1 ± 8.5 | ivGC + OD | 2-walls | 6 |
| Guo et al (6) | 2022 | China | PCS | 27 | 13/14 | 44 | 53.7 ± 8.8 | ivGC, ivGC + OD | 2-walls | ivGC: 1.8 ± 1.5 ivGC + OD: 2.6 ± 1.6 |
| Study . | Year . | Country . | Study design . | Patients (n) . | Sex (M/ F) . | Orbits (n) . | Mean age (y) . | Intervention . | OD (Orbits) . | Mean follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Wakelkamp et al (9) | 2005 | Netherlands | RCT | 15 | 2/13 | 15 | 52 | ivGC, OD | 3-walls | ivGC: 78 ± 15.5 OD: 64 ± 13 |
| Simon et al (13) | 2006 | Israel | RCS | 20 | 4/16 | 26 | 50.3 ± 15.7 | ivGC + OD | 2-walls: 6 | 17 ± 9 |
| Liao et al (14) | 2006 | Taiwan, China | RCS | 22 | 8/14 | 38 | 58.4 | ivGC + OD | 2-walls | 22.3 ± 12.8 |
| Lipski et al (15) | 2011 | Germany | RCS | 15 | 1/14 | 30 | 56.2 ± 10.88 | OD | 3-walls | 30 ± 13 |
| Wu et al (10) | 2011 | China | RCS | 29 | 10/19 | 45 | 44.8 ± 13.8 | OD | 2-walls | 17.4 ± 5.6 |
| Baril et al (16) | 2014 | Spain | RCS | 34 | 20/39 | 59 | 57.80 ± 11.89 | ivGC + OD | 2-walls | 132 |
| Korkmaz et al (17) | 2015 | Turkey | RCS | 42 | 25/17 | 68 | 53.5 | OD | 2-walls: 41 3-walls: 27 | 39.3 ± 15 |
| Lv et al (18) | 2015 | China | RCS | 43 | 12/31 | 72 | 45 | OD | fat decompression | 9 ± 3 |
| Kuebler et al (19) | 2020 | Germany | RA | 25 | 5/20 | 46 | ivGC: 62 ivGC + OD: 55 | ivGC, ivGC + OD | 3-walls | ivGC: 12 ± 12.55 ivGC + OD:10.1 ± 4.51 |
| Tagami et al (20) | 2020 | Japan | RCS | 44 | 15/29 | 70 | 53.4 ± 8.9 | OD | 2-walls | 40.9 ± 21.2 |
| Woods et al (21) | 2020 | Ireland | RA | 22 | 7/15 | 17 | 52 | ivGC + OD | 2-walls | 3 ± 0 |
| Xu et al (5) | 2020 | China | PCS | 23 | 15/8 | 46 | 58.3 ± 8.93 | ivGC, ivGC + OD | 2-walls | 3 ± 0 |
| Cheng et al (22) | 2021 | China | RCS | 37 | 9/28 | 52 | 48.27 ± 10.59 | OD | 2-walls:31 3-walls:21 | 22 ± 17 |
| Tu et al (23) | 2021 | China | RA | 42 | 24/18 | 74 | 57.30 ± 9.29 | OD | 2-walls | 6 ± 1.5 |
| Rezar-Dreindl et al (3) | 2022 | Austria | RA | 49 | 12/37 | 98 | 52 ± 14 | ivGC, OD, ivGC + OD | 2-walls:8 3-walls:30 | 49.2 ± 33.6 |
| Yun et al (2) | 2022 | Taiwan, China | RA | 11 | 9/2 | 16 | 60.1 ± 8.5 | ivGC + OD | 2-walls | 6 |
| Guo et al (6) | 2022 | China | PCS | 27 | 13/14 | 44 | 53.7 ± 8.8 | ivGC, ivGC + OD | 2-walls | ivGC: 1.8 ± 1.5 ivGC + OD: 2.6 ± 1.6 |
Abbreviations: DON, dysthyroid optic neuropathy; ivGC, intravenous high-dose glucocorticoids; OD, orbital decompression; PCS, prospective cohort study; RA, retrospective analysis; RCS, retrospective case studies; RCT, randomized controlled trial.
Baseline characteristics of the patients with DON included in the meta-analysis
| Study . | Year . | Country . | Study design . | Patients (n) . | Sex (M/ F) . | Orbits (n) . | Mean age (y) . | Intervention . | OD (Orbits) . | Mean follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Wakelkamp et al (9) | 2005 | Netherlands | RCT | 15 | 2/13 | 15 | 52 | ivGC, OD | 3-walls | ivGC: 78 ± 15.5 OD: 64 ± 13 |
| Simon et al (13) | 2006 | Israel | RCS | 20 | 4/16 | 26 | 50.3 ± 15.7 | ivGC + OD | 2-walls: 6 | 17 ± 9 |
| Liao et al (14) | 2006 | Taiwan, China | RCS | 22 | 8/14 | 38 | 58.4 | ivGC + OD | 2-walls | 22.3 ± 12.8 |
| Lipski et al (15) | 2011 | Germany | RCS | 15 | 1/14 | 30 | 56.2 ± 10.88 | OD | 3-walls | 30 ± 13 |
| Wu et al (10) | 2011 | China | RCS | 29 | 10/19 | 45 | 44.8 ± 13.8 | OD | 2-walls | 17.4 ± 5.6 |
| Baril et al (16) | 2014 | Spain | RCS | 34 | 20/39 | 59 | 57.80 ± 11.89 | ivGC + OD | 2-walls | 132 |
| Korkmaz et al (17) | 2015 | Turkey | RCS | 42 | 25/17 | 68 | 53.5 | OD | 2-walls: 41 3-walls: 27 | 39.3 ± 15 |
| Lv et al (18) | 2015 | China | RCS | 43 | 12/31 | 72 | 45 | OD | fat decompression | 9 ± 3 |
| Kuebler et al (19) | 2020 | Germany | RA | 25 | 5/20 | 46 | ivGC: 62 ivGC + OD: 55 | ivGC, ivGC + OD | 3-walls | ivGC: 12 ± 12.55 ivGC + OD:10.1 ± 4.51 |
| Tagami et al (20) | 2020 | Japan | RCS | 44 | 15/29 | 70 | 53.4 ± 8.9 | OD | 2-walls | 40.9 ± 21.2 |
| Woods et al (21) | 2020 | Ireland | RA | 22 | 7/15 | 17 | 52 | ivGC + OD | 2-walls | 3 ± 0 |
| Xu et al (5) | 2020 | China | PCS | 23 | 15/8 | 46 | 58.3 ± 8.93 | ivGC, ivGC + OD | 2-walls | 3 ± 0 |
| Cheng et al (22) | 2021 | China | RCS | 37 | 9/28 | 52 | 48.27 ± 10.59 | OD | 2-walls:31 3-walls:21 | 22 ± 17 |
| Tu et al (23) | 2021 | China | RA | 42 | 24/18 | 74 | 57.30 ± 9.29 | OD | 2-walls | 6 ± 1.5 |
| Rezar-Dreindl et al (3) | 2022 | Austria | RA | 49 | 12/37 | 98 | 52 ± 14 | ivGC, OD, ivGC + OD | 2-walls:8 3-walls:30 | 49.2 ± 33.6 |
| Yun et al (2) | 2022 | Taiwan, China | RA | 11 | 9/2 | 16 | 60.1 ± 8.5 | ivGC + OD | 2-walls | 6 |
| Guo et al (6) | 2022 | China | PCS | 27 | 13/14 | 44 | 53.7 ± 8.8 | ivGC, ivGC + OD | 2-walls | ivGC: 1.8 ± 1.5 ivGC + OD: 2.6 ± 1.6 |
| Study . | Year . | Country . | Study design . | Patients (n) . | Sex (M/ F) . | Orbits (n) . | Mean age (y) . | Intervention . | OD (Orbits) . | Mean follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|
| Wakelkamp et al (9) | 2005 | Netherlands | RCT | 15 | 2/13 | 15 | 52 | ivGC, OD | 3-walls | ivGC: 78 ± 15.5 OD: 64 ± 13 |
| Simon et al (13) | 2006 | Israel | RCS | 20 | 4/16 | 26 | 50.3 ± 15.7 | ivGC + OD | 2-walls: 6 | 17 ± 9 |
| Liao et al (14) | 2006 | Taiwan, China | RCS | 22 | 8/14 | 38 | 58.4 | ivGC + OD | 2-walls | 22.3 ± 12.8 |
| Lipski et al (15) | 2011 | Germany | RCS | 15 | 1/14 | 30 | 56.2 ± 10.88 | OD | 3-walls | 30 ± 13 |
| Wu et al (10) | 2011 | China | RCS | 29 | 10/19 | 45 | 44.8 ± 13.8 | OD | 2-walls | 17.4 ± 5.6 |
| Baril et al (16) | 2014 | Spain | RCS | 34 | 20/39 | 59 | 57.80 ± 11.89 | ivGC + OD | 2-walls | 132 |
| Korkmaz et al (17) | 2015 | Turkey | RCS | 42 | 25/17 | 68 | 53.5 | OD | 2-walls: 41 3-walls: 27 | 39.3 ± 15 |
| Lv et al (18) | 2015 | China | RCS | 43 | 12/31 | 72 | 45 | OD | fat decompression | 9 ± 3 |
| Kuebler et al (19) | 2020 | Germany | RA | 25 | 5/20 | 46 | ivGC: 62 ivGC + OD: 55 | ivGC, ivGC + OD | 3-walls | ivGC: 12 ± 12.55 ivGC + OD:10.1 ± 4.51 |
| Tagami et al (20) | 2020 | Japan | RCS | 44 | 15/29 | 70 | 53.4 ± 8.9 | OD | 2-walls | 40.9 ± 21.2 |
| Woods et al (21) | 2020 | Ireland | RA | 22 | 7/15 | 17 | 52 | ivGC + OD | 2-walls | 3 ± 0 |
| Xu et al (5) | 2020 | China | PCS | 23 | 15/8 | 46 | 58.3 ± 8.93 | ivGC, ivGC + OD | 2-walls | 3 ± 0 |
| Cheng et al (22) | 2021 | China | RCS | 37 | 9/28 | 52 | 48.27 ± 10.59 | OD | 2-walls:31 3-walls:21 | 22 ± 17 |
| Tu et al (23) | 2021 | China | RA | 42 | 24/18 | 74 | 57.30 ± 9.29 | OD | 2-walls | 6 ± 1.5 |
| Rezar-Dreindl et al (3) | 2022 | Austria | RA | 49 | 12/37 | 98 | 52 ± 14 | ivGC, OD, ivGC + OD | 2-walls:8 3-walls:30 | 49.2 ± 33.6 |
| Yun et al (2) | 2022 | Taiwan, China | RA | 11 | 9/2 | 16 | 60.1 ± 8.5 | ivGC + OD | 2-walls | 6 |
| Guo et al (6) | 2022 | China | PCS | 27 | 13/14 | 44 | 53.7 ± 8.8 | ivGC, ivGC + OD | 2-walls | ivGC: 1.8 ± 1.5 ivGC + OD: 2.6 ± 1.6 |
Abbreviations: DON, dysthyroid optic neuropathy; ivGC, intravenous high-dose glucocorticoids; OD, orbital decompression; PCS, prospective cohort study; RA, retrospective analysis; RCS, retrospective case studies; RCT, randomized controlled trial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
